Lurking epidemic of hepatitis C virus infection in Iran: A call

to action by Taherkhani, Reza & Farshadpour, Fatemeh
Reza Taherkhani, Fatemeh Farshadpour 
LETTERS TO THE EDITOR
1040 August 28, 2017|Volume 9|Issue 24|WJH|www.wjgnet.com
Lurking epidemic of hepatitis C virus infection in Iran: A call 
to action
Reza Taherkhani, the Persian Gulf Biomedical Research Center, 
Bushehr University of Medical Sciences, Bushehr 7514633341, 
Iran
Fatemeh Farshadpour, the Persian Gulf Tropical Medicine 
Research Center, Bushehr University of Medical Sciences, Bushehr 
7514633341, Iran 
ORCID number: Reza Taherkhani (0000-0001-6499-0531); 
Fatemeh Farshadpour (0000-0002-8317-9573).
Author contributions: Taherkhani R and Farshadpour F both 
contributed to this manuscript. 
Conflict-of-interest statement: The authors declare there are 
no conflicts of interest in the content of this manuscript.
Open-Access: This article is an open-access article which was 
selected by an in-house editor and fully peer-reviewed by external 
reviewers. It is distributed in accordance with the Creative 
Commons Attribution Non Commercial (CC BY-NC 4.0) license, 
which permits others to distribute, remix, adapt, build upon this 
work non-commercially, and license their derivative works on 
different terms, provided the original work is properly cited and 
the use is non-commercial. See: http://creativecommons.org/
licenses/by-nc/4.0/
Manuscript source: Invited manuscript
Correspondence to: Fatemeh Farshadpour, PhD, the Persian 
Gulf Tropical Medicine Research Center, Bushehr University of 




Received: May 4, 2017
Peer-review started: May 4, 2017
First decision: June 15, 2017
Revised: June 19, 2017
Accepted: July 14, 2017
Article in press: July 17, 2017
Published online: August 28, 2017
Abstract
Despite having a relatively low prevalence in the 
Iranian general population, the burden of hepatitis C 
virus (HCV) infection is on the rise, and hepatitis C is 
predicted to be the most important leading cause of 
viral hepatitis-related mortality in the near future in Iran. 
The recent population-based epidemiological studies have 
revealed the predominant role of injecting drug use in 
increasing prevalence of HCV infection. Undoubtedly, 
new management paradigm is required to drive down 
the rising wave of hepatitis C in Iran. Priority should be 
given to young injecting drug users as the cornerstone 
of the lurking epidemic of HCV infection in Iran.
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Core tip: Iran is known as a low-endemic country for 
hepatitis C virus (HCV) infection, while the recent popu-
lation-based epidemiological studies have revealed 
the increasing burden of HCV infection in the Iranian 
population. The asymptomatic nature of HCV infection 
and the undiagnosed HCV-infected injecting drug 
users have fueled this increase. Obviously, the current 
management paradigm is inadequate if control of HCV 
infection is aimed to be achieved.
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TO THE EDITOR
Less than 0.5% of the population, as many as 186500 
patients are infected with hepatitis C virus (HCV) in 
Iran[1]. The majority of HCV-positive patients have 
been infected by injecting drug use, equivalent to 75% 
of the HCV-infected population[2]. The burden of HCV 
infection shows a rising trend, and HCV infection is 
projected to be the most important leading cause of 
viral hepatitis-related mortality in the near future in 
Iran[1,3]. Obviously, the current management paradigm 
is inadequate if control of HCV infection is aimed to be 
achieved. 
Mandatory screening of all blood donors for hepatitis 
C resulted in a remarkable decrease in the prevalence 
of HCV infection[1,2,4,5]. In view of the success in the 
Iranian Blood Transfusion Organisation, the talk of 
HCV elimination has been intensified. However, all 
hopes came to knot due to rising wave of HCV infection 
among injecting drug users (IDUs), those whom 
the control of HCV transmission among is the most 
difficult. The shared use of drug paraphernalia and 
lack of awareness among young IDUs regarding the 
risk of acquiring HCV infection via needle-sharing are 
the root cause of the increasing prevalence of HCV 
infection among IDUs community[1]. At the same time, 
the asymptomatic nature of HCV infection and the 
undiagnosed HCV-infected IDUs would accelerate this 
increase[1]. 
The recent changes in the genotype distribution 
of HCV have also fueled this epidemic[6]. High rates 
of mutation in HCV genome have resulted in the 
emergence of seven major genotypes and at least 
67 subtypes[7]. Each geographic region has a distinct 
genotypic pattern, which depends on the predominant 
mode of transmission, risk factors, life style, the source 
of infection, disease transmission patterns and age 
distribution in that particular region[8,9]. These geno-
typic patterns are not constant, change overtime and 
influence the epidemiology of HCV infection in that 
region[10,11]. The most prevalent subtype in Iran is 1a, 
followed by 3a and 1b. Over the last decade, however, 
a gradual decrease in the frequency of subtypes 1a and 
1b and an increase in subtype 3a have been reported 
due to changes in the routes of transmission of HCV 
from blood transfusion to injecting drug use[6,9-12]. 
These changes should be taken in to consideration 
to establish better strategies for managing the silent 
epidemic of hepatitis C in Iran.
Another challenge is treatment of HCV-infected 
population. Despite having poor tolerability, prolonged 
treatment course and frequent side effects, interferon 
(IFN)-based therapy is still recommended as the 
first-line therapy in Iran due to affordability and local 
availability[3,9]. Annually, 2.4% of the Iranian HCV-
infected population is treated by pegylated IFN plus 
ribavirin, with approximately 58%-78% of patients 
showing a sustained virological response (SVR) de-
pending on the HCV genotype[2]. Introduction of IFN-
free direct-acting antivirals (DAAs) has revolutionized 
the treatment course of HCV infection due to superior 
rates of SVR, favorable tolerability, fewer side effects 
and shorter treatment period[13-15]. However, in reality, 
the restricted accessibility and high price of DAAs 
outweigh these benefits. Recently, the production of 
a domestic DAA, the combination of daclatasvir and 
sofosbuvir, with health insurance coverage has been 
announced in Iran, paving the way for low-cost access 
to DAAs and subsequently widespread use of these 
drugs in the near future[1,3]. This domestically produced 
DAA, Sovodak, has shown favorable SVR rates in 
Iranian patients infected with genotypes 1 or 3 HCV, 
the most predominant genotypes in Iran, providing 
an opportunity to improve the treatment rate and 
subsequently eliminate HCV infection in the future[1].
These challenges in the management of hepatitis 
C epidemic cannot be neglected any longer. Resent 
changes in the epidemiology of HCV would demand 
changes in health policies, prevention and management 
strategies. In view of the success of the transfusion-
safety measures implemented in the Iranian Blood 
Transfusion Organization[4,9], screening of high-risk 
populations for hepatitis C, new therapeutic strategies 
with an emphasis on timely diagnosis and treatment, 
expansion of harm-reduction interventions, public 
education regarding the risk of HCV infection, as well as 
comprehensive cooperation and mobilization of health 
care providers are required to drive down the rising 
wave of HCV infection in Iran once again. Priority should 
be given to young IDUs as the cornerstone of this silent 
epidemic. Furthermore, national health policies should 
be prioritized in a way to curb the lurking epidemic of 
HCV infection once and for all. 
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